¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2021 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(2ÀÏÂ÷) : 2021-12-04

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2021 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(2ÀÏÂ÷) : 2021-12-04
±³À°ÀÏÀÚ : 2021-12-04
±³À°Àå¼Ò : µå·¡°ï½ÃƼ ÇѶóȦ  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ  
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520  
À̸ÞÀÏ : retina@retina.or.kr      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 7ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í Á¤È¸¿ø(2020³âµµ ¿¹ºñȸ¿ø Æ÷ÇÔ): µî·Ïºñ ¸éÁ¦(¿¬È¸ºñ ³³ºÎÀÚ¿¡ ÇÑÇÔ) ÇöÁ÷ Àü°øÀÇ ¹× Æç·Î¿ì 4¸¸¿ø ±× ¿Ü 6¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-04 ÇѶóȦ 09:00~09:08 Associations between choriocapillaris flow on optical coherence tomography angiography and cardiovascular risk profile in patients with acute myocardial infarction  ½Å¿ë¿î(ÇѾç´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 09:08~09:16 Close correlation between renal function and choroidal thickness  ±èÁöÅÃ(Áß¾Ó´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 09:16~09:24 ÀüÀ̼º ¾È±¸³» Á¾¾ç  ±è¹Î(¿¬¼¼´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 09:24~09:32 A case of atypical necrotizing viral retinitis in patient with acquired immunodeficiency syndrome  ±è·¡¿µ(°¡Å縯´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 09:32~09:40 Intraocular Inflammation Occurrence After The Use Of Anti-adhesion Agents  ÀÌ»óÁØ(°í½Å´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 09:40~09:48 Inner Retinal Changes in Eyes with Hydroxychloroquine Retinopathy  ¾È¼ºÁØ(ÇѾç´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 09:48~09:56 SARS-CoV-2 vaccine-induced RVO and submacular hemorrhage in AMD  À̽±Ô(¿¬¼¼´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:00~10:09 Development of intraretinal fluid in neovascular age-related macular degeneration during anti-vascular endothelial growth factor treatment  Á¶ÇÑÁÖ(±è¾È°úº´¿ø) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:08~10:16 A novel findings of morphologic characteristics of neovascular AMD with tolerable subretinal fluid  À̺´·Î(ÇѾç´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:16~10:24 Predictors of retinal fluid after anti-VEGF treatment of neovascular age-related macular degeneration: post hoc analysis from the PROOF stud  »ç°ø¹Î(¿µ³²´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:24~10:32 ¸Æ¶ô¸·ºñÈÄ(pachychoroid) ´«¿¡¼­ ³ë¸¥ÀÚ¸ð¾ç º´º¯(vitielliform lesion)  ÀÌ¿ø±â(´©³×¾È°úº´¿ø) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:32~10:40 »ïÃ⼺ ³ªÀÌ°ü·Ã Ȳ¹Ýº¯¼º ȯÀÚÀÇ ½Å»ýÇ÷°ü ¹®ÇÕ¿¡ ´ëÇÑ Á¤·®Àû ºÐ¼®°ú Àç¹ßºóµµ¿ÍÀÇ ¿¬°ü¼º  ÀÌÇü¿ì(°Ç±¹´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:40~10:48 Ä¡·á°¡ Áß´ÜµÈ ½À¼º ³ªÀÌ°ü·ÃȲ¹Ýº¯¼º¿¡¼­ °æ°ú°üÂû Áß ¹ß»ýÇÏ´Â ¸Á¸·ÇÏÃâÇ÷  ±èÀçÈÖ(±è¾È°úº´¿ø) 
±³À°½Ã°£ 12-04 ÇѶóȦ 10:48~10:56 Looking inside the exudative age-related macular degeneration at an aspect of non-exudative AMD  À±Ã¶¹Î(°í·Á´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 11:00~11:23 È²¹Ý¼ö¼ú¿¡¼­ ¿ì¸®°¡ °í·ÁÇÏÁö ¾Ê¾Ò´ø »çÇ׵頠±è¼øÇö(´©³×¾È°úº´¿ø) 
±³À°½Ã°£ 12-04 ÇѶóȦ 11:23~11:46 Automated segmentation and prediction of OCT images using deep learning in AMD  ±èÇüÂù(°Ç±¹´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 11:46~12:09 PCV: A mysterious disease  ÀÌ¿ø±â(´©³×¾È°úº´¿ø) 
±³À°½Ã°£ 12-04 ÇѶóȦ 13:25~13:23 OCT alone is sufficient  À̹̿¬(°¡Å縯´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 13:23~13:41 OCT-A is necessary for better decision  Á¶ÇÑÁÖ(±è¾È°úº´¿ø) 
±³À°½Ã°£ 12-04 ÇѶóȦ 13:41~13:49 #NAME?  ¹è°ÇÈ£(¼­¿ï´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 13:49~13:57 I prefer oral mineralocorticoid or anti-VEGF  ÇÑ¿ë¼·(°æ»ó´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 13:57~14:05 #NAME?  ±èÀ±Àü(¿ï»ê´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:05~14:13 I try IV thrombolysis  ¿ì¼¼ÁØ(¼­¿ï´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:13~14:19 Scleral buckling  À̽¿ì(µ¿±¹´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:19~14:25 Vitrectomy  ÀÌ¿µÈÆ(°Ç¾ç´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:25~14:32 Combined SB & vitrectomy  Áö¿µ¼®(Àü³²´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:32~14:40 Prophylactic 360¡Æ laser is useful in preventing post-op RRD  °­½Â¹ü(°¡Å縯´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:40~14:48 There is no reason to perform 360¡Æ prophylactic laser  ±èÀÀ¼®(°æÈñ´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 14:51~15:07 Ultra-widefield imaging  »ç°ø¹Î(¿µ³²´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 15:07~15:19 Vitreoretinal surgery  ¹Úµ¿È£(°æºÏ´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 15:19~15:31 Gene therapy for RPE65 mutation-associated retinal dystrophy  ±è»óÁø(¼º±Õ°ü´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 15:31~15:43 What¡¯s new in hereditary retinal diseases  ¾ÈÁöÀ±(¼­¿ï´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 15:43~15:51 Epidemiology in Retina  Áöµ¿Çö(°¡Å縯´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 15:51~16:07 What¡¯s new in ocular oncology  ±è¹Î(¿¬¼¼´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 16:15~16:23 °øÅëÀÚ·á¸ðµ¨À» ÀÌ¿ëÇÑ ¾È°ú ¿µ¿ª ¿¬±¸ÀÇ Ãʱ⠰æÇèµé - ¹ß»ý·ü ¿¬±¸, Ä¡·á ºÎ´ã ¹× Ä¡·á ÆÐÅÏ¿¡ ´ëÇÑ ¿¬±¸ µî 3°³ ¿¬±¸ °á°ú¸¦ Áß½ÉÀ¸·Î  ¹Ú»óÁØ(¼­¿ï´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 16:23~16:31 OCT & OCTA: where are we now?  ÀÌÁÖÀº(Á¦¾È°ú) 
±³À°½Ã°£ 12-04 ÇѶóȦ 16:31~16:39 Three Monthly Intravitreal Anti-VEGF Injections with Panretinal Photocoagulation for High-Risk Proliferative Diabetic Retinopathy  ¹èÁ¤ÈÆ(¼º±Õ°ü´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 16:39~16:47 Automated Segmentation of Retinal Capillary Non-Perfusion and Neovascularization on Ultra-Wide-Field Retinal Fluorescein Angiography of Diabetic Retinopathy using Deep Learning  ¹éÁö¿ø(°¡Å縯´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 16:47~16:51 A Study of the Association Between Retinal Vessel Geometry and Optical Coherence Tomography Angiography Metrics in Diabetic Retinopathy  ¸¶´ëÁß(ÇѸ²´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 16:51~17:03 Serum and aqueous humor adiponectin levels correlate with diabetic retinopathy development and progression  ¾çÇö½Â(½Å¼¼°è¾È°ú) 
±³À°½Ã°£ 12-04 ÇѶóȦ 17:03~17:11 Áß½ÉÀå¾×¼º¸Æ¶ô¸Á¸·º´Áõ ȯÀÚ¿¡¼­ Ȳ¹Ý ¹× À¯µÎÁÖÀ§ ¸Æ¶ô¸· Ư¡ ºñ±³  ±è¿µÈ£(°í·Á´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 17:11~17:19 The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial  ³ë¿µÁ¤(°¡Å縯´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 17:25~17:35 Çмú»ó °­¿¬  À̽±Ô(¿¬¼¼´ë) 
±³À°½Ã°£ 12-04 ÇѶóȦ 17:35~17:45 Çмú»ó °­¿¬  ÀÓÇüºó(´ëÀü¸í¾È°ú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2021 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(2ÀÏÂ÷) : 2021-12-04""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦4ȸ ¾ÆžÈƼ¿¡ÀÌ¡ÄÁÆÛ·±½º : 2021-12-04
´ÙÀ½±Û ´ëÇѽ½°üÀýÇÐȸ Á¦13ȸ ¿¬¼ö°­Á : 2021-12-04
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 6 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 6 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 4 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 4 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 6 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 4 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 1 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 1 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 1 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 3 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 2 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 1 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 3 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 2 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 5 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷